company background image
CL logo

Cresco Labs CNSX:CL Stock Report

Last Price

CA$0.88

Market Cap

CA$395.4m

7D

4.8%

1Y

-67.3%

Updated

21 Apr, 2025

Data

Company Financials +

CL Stock Overview

Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States. More details

CL fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Community vs My Fair Value

Select a narrative for quick price alerts from the community, or create your own.

CA$2.63
FV
66.5% undervalued intrinsic discount
-0.42%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
6 days ago author updated this narrative

Cresco Labs Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cresco Labs
Historical stock prices
Current Share PriceCA$0.88
52 Week HighCA$3.58
52 Week LowCA$0.75
Beta2.04
1 Month Change-13.73%
3 Month Change-31.25%
1 Year Change-67.29%
3 Year Change-86.59%
5 Year Change-85.69%
Change since IPO-86.56%

Recent News & Updates

Recent updates

author-image

Expanding Production In Illinois, Pennsylvania And Kentucky Will Meet Demand

Mar 29 Expansion in Illinois and Pennsylvania and entry into Kentucky's market aim to boost revenue growth and market share.

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 27%

Mar 07
Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 27%

Is Cresco Labs (CSE:CL) A Risky Investment?

Jan 31
Is Cresco Labs (CSE:CL) A Risky Investment?

Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Dec 14
Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Oct 24
Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Aug 11
Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Jul 17
Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Jun 19
Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 19
Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Mar 16
Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Mar 03
Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Jan 26
Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Jan 04
Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Is Cresco Labs (CSE:CL) Using Too Much Debt?

Sep 22
Is Cresco Labs (CSE:CL) Using Too Much Debt?

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Aug 11
Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

Jan 25
Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?

Dec 13
Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?

We Think Cresco Labs (CSE:CL) Is Taking Some Risk With Its Debt

Aug 22
We Think Cresco Labs (CSE:CL) Is Taking Some Risk With Its Debt

Shareholder Returns

CLCA PharmaceuticalsCA Market
7D4.8%2.4%0.7%
1Y-67.3%-62.4%7.8%

Return vs Industry: CL underperformed the Canadian Pharmaceuticals industry which returned -60% over the past year.

Return vs Market: CL underperformed the Canadian Market which returned 9% over the past year.

Price Volatility

Is CL's price volatile compared to industry and market?
CL volatility
CL Average Weekly Movement13.0%
Pharmaceuticals Industry Average Movement12.7%
Market Average Movement9.5%
10% most volatile stocks in CA Market17.8%
10% least volatile stocks in CA Market4.0%

Stable Share Price: CL has not had significant price volatility in the past 3 months compared to the Canadian market.

Volatility Over Time: CL's weekly volatility (13%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a2,900Charlie Bachtellwww.crescolabs.com

Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company offers cannabis flowers under the FloraCal brand; and cannabis oils and variety of bites are available at multiple potency levels under the Mindy’s Edibles brand, as well as licenses the Kiva brand.

Cresco Labs Inc. Fundamentals Summary

How do Cresco Labs's earnings and revenue compare to its market cap?
CL fundamental statistics
Market capCA$395.37m
Earnings (TTM)-CA$102.98m
Revenue (TTM)CA$990.22m

0.3x

P/S Ratio

-3.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CL income statement (TTM)
RevenueUS$715.76m
Cost of RevenueUS$359.89m
Gross ProfitUS$355.87m
Other ExpensesUS$430.31m
Earnings-US$74.44m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.21
Gross Margin49.72%
Net Profit Margin-10.40%
Debt/Equity Ratio97.0%

How did CL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/21 18:27
End of Day Share Price 2025/04/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cresco Labs Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Capital Markets
Russell StanleyBeacon Securities Limited